Small cell lung cancer: Will recent progress lead to improved outcomes? Journal Article
| Authors: | Pietanza, M. C.; Byers, L. A.; Minna, J. D.; Rudin, C. M. |
| Article Title: | Small cell lung cancer: Will recent progress lead to improved outcomes? |
| Abstract: | Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here. © 2015 American Association for Cancer Research. |
| Keywords: | cancer survival; treatment outcome; gene mutation; overall survival; thalidomide; cancer recurrence; sorafenib; bevacizumab; sunitinib; nonhuman; alpha interferon; cancer radiotherapy; topotecan; medical decision making; imatinib; bcg vaccine; interleukin 2; ipilimumab; unindexed drug; progression free survival; bortezomib; computer assisted tomography; gene expression profiling; etoposide; drug screening; chemosensitivity; cancer research; transgenic mouse; cixutumumab; temsirolimus; disease model; tumor suppressor gene; gamma interferon; genetic engineering; radiation dose fractionation; early diagnosis; tipifarnib; cediranib; vandetanib; radiosensitivity; consensus development; thorax radiography; metastasis potential; platinum complex; lung carcinogenesis; endoscopic biopsy; bioinformatics; everolimus; obatoclax; oblimersen; marimastat; small cell lung cancer; randomized controlled trial (topic); clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); desipramine; tanomastat; navitoclax; fine needle aspiration biopsy; vismodegib; human; priority journal; article; erdafitinib; mitumomab |
| Journal Title: | Clinical Cancer Research |
| Volume: | 21 |
| Issue: | 10 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-15 |
| Start Page: | 2244 |
| End Page: | 2255 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-14-2958 |
| PROVIDER: | scopus |
| PMCID: | PMC4497796 |
| PUBMED: | 25979931 |
| DOI/URL: | |
| Notes: | Export Date: 2 October 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work